紫杉醇脂质体联合顺铂治疗晚期NSCLC的效果及对肿瘤标志物、近期预后的影响  

Effect of paclitaxel liposome combined with cisplatin on advanced NSCLC and the influence on tumor markers and short-term prognosis

作　　者：李银英[1] 郭丽芳[1] 周建华[1] 焦红军[1] Li Yinying;Guo Lifang;Zhou Jianhua;Jiao Hongjun(Department of Pharmacy,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第二附属医院药学部,450052

出　　处：《临床医学》2023年第5期88-91,共4页Clinical Medicine

摘　　要：目的 观察紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌(NSCLC)的效果及对肿瘤标志物、近期预后的影响。方法 选取2020年1月至2021年12月郑州大学第二附属医院收治的68例晚期NSCLC患者为研究对象,根据化疗方案不同分为对照组(n=32)与观察组(n=36),对照组采用吉西他滨联合顺铂治疗,观察组采用紫杉醇脂质体联合顺铂治疗,比较两组临床疗效、肿瘤标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)]、不良反应发生率及1年生存率。结果 两组肺部原发病灶客观缓解率和疾病控制率比较,差异未见统计学意义(P>0.05);观察组区域淋巴结客观缓解率和疾病控制率为47.22%、86.11%,高于对照组(21.88%和62.50%),差异有统计学意义(P<0.05)。治疗后观察组血清CYFRA21-1、CA125、NSE、CEA水平低于对照组,差异有统计学意义(P<0.05)。观察组血小板减少、胃肠道反应发生率低于对照组,差异有统计学意义(P<0.05),两组贫血、脱发、肝功能损伤、肾功能损伤及过敏发生率比较,差异未见统计学意义(P>0.05)。观察组1年生存率高于对照组,差异有统计学意义(P<0.05)。结论 紫杉醇脂质体联合顺铂治疗晚期NSCLC效果显著,可降低肿瘤标志物,减少不良反应,提高生存率。Objective To observe the effect of paclitaxel liposome combined with cisplatin on advanced non-small cell lung cancer(NSCLC) and the influence on tumor markers and short-term prognosis.Methods A total of 68 patients with advanced NSCLC who were admitted to the Second Affiliated Hospital of Zhengzhou University from January 2020 and December 2021 were selected as the research subjects.According to different chemotherapy regiments,they were divided into control group(n=32) and observation group(n=36).On basis of cisplatin,the control group was treated with gemcitabine,while the observation group was treated with paclitaxel liposome.The clinical curative effect,tumor markers [cytokeratin 19 fragment antigen 21-1(CYFRA21-1),cancer antigen 125(CA125),neuron-specific enolase(NSE),carcinoembryonic antigen(CEA)],incidence of adverse reactions and 1-year survival rate were compared between the two groups.Results There was no significant difference in objective remission rate and disease control rate of primary lung lesions between the two groups(P>0.05).The objective remission rate and disease control rate of regional lymph nodes in observation group were 47.22% and 86.11%,which was higher than those in control group(21.88%,62.50%,P<0.05).After treatment,the levels of CYFRA21-1,CA125,NSE and CEA in observation group were lower than those in control group(P<0.05).The incidences of thrombocytopenia and gastrointestinal reactions in observation group were lower than those in control group(P<0.05),but there was no significant difference in the incidence of anemia,alopecia,liver function injury,renal function injury and allergy between the two groups(P>0.05).The 1-year survival rate in observation group was higher than that in control group(86.11% vs 59.38%,P<0.05).Conclusions The curative effect of paclitaxel liposome combined with cisplatin is significant on advanced NSCLC,which can reduce levels of tumor markers and adverse reactions,and improve survival rate.

关 键 词：晚期非小细胞肺癌 紫杉醇脂质体 顺铂 肿瘤标志物 近期预后 

分 类 号：R734.2[医药卫生—肿瘤]